RECURRENT HIGH-GRADE GLIOMA
Clinical trials for RECURRENT HIGH-GRADE GLIOMA explained in plain language.
Never miss a new study
Get alerted when new RECURRENT HIGH-GRADE GLIOMA trials appear
Sign up with your email to follow new studies for RECURRENT HIGH-GRADE GLIOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Stem cells and immunotherapy join forces against childhood brain tumors
Disease control OngoingThis early-stage trial tests a new approach for children whose high-grade glioma has come back after standard treatments. It combines specially grown stem cells with an immunotherapy drug called nivolumab. The main goals are to see if the treatment is safe and possible to deliver…
Matched conditions: RECURRENT HIGH-GRADE GLIOMA
Phase: PHASE1 • Sponsor: University of Florida • Aim: Disease control
Last updated May 17, 2026 02:06 UTC
-
RNA vaccine trial offers new hope for kids with Hard-to-Treat cancers
Disease control OngoingThis study tests a new RNA vaccine for children and young adults (ages 3-25) with recurrent high-grade glioma (a brain cancer) or osteosarcoma (a bone cancer). The vaccine aims to train the body's immune system to attack cancer cells. The trial will check safety, the right dose, …
Matched conditions: RECURRENT HIGH-GRADE GLIOMA
Phase: PHASE1, PHASE2 • Sponsor: University of Florida • Aim: Disease control
Last updated May 15, 2026 11:58 UTC
-
Virus injection takes on deadly brain tumors
Disease control ENROLLING_BY_INVITATIONThis study tests a new treatment for people whose high-grade glioma (a fast-growing brain tumor) has come back after standard therapy. The treatment is a modified virus injected into the brain that is designed to attack cancer cells and boost the immune system. The trial will enr…
Matched conditions: RECURRENT HIGH-GRADE GLIOMA
Phase: PHASE1, PHASE2 • Sponsor: Beijing Bio-Targeting Therapeutics Technology Co., Ltd • Aim: Disease control
Last updated Apr 26, 2026 20:01 UTC